• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 482999 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414747839 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414747839 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Keryx Biopharmaceuticals Makes a Move: Up 2.2%

Published on Fri, 04/19/2013 - 12:25
By Robert Cotter

Keryx Biopharmaceuticals (NASDAQ:KERX) is one of today's biggest movers, up 2.2% to $7.78. The S&P is trading higher by 0.5% to 1,550 and the Dow is trading 0.3% lower to 14,499.

In the past 52 weeks, shares of Keryx Biopharmaceuticals have traded between a low of $1.28 and a high of $9.98 and are now at $7.78, which is 508% above that low price. Over the past week, the 200-day moving average (MA) has gone up 3.2% while the 50-day MA has advanced 0.3%.

Keryx Biopharmaceuticals (NASDAQ:KERX) has potential upside of 65.3% based on a current price of $7.78 and analysts' consensus price target of $12.86. The stock should find initial support at its 50-day moving average (MA) of $7.14 and further support at its 200-day MA of $3.82.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinold compound for the treatment of diabetic nephropathy.

By Robert Cotter
rcotter@fnno.com

Latest News from FNNO

Take-Two Interactive Software Looks to C...

Shares of Take-Two Interactive Software (NASDAQ:TTWO) traded at a new 52-week high toda ...

Shares of Talisman Energy Fall Below Pre...

Shares of Talisman Energy (NYSE:TLM) traded at a new 52-week low today of $6.12. Appro ...

Recent 52-Week High Exceeded in Shares o...

Shares of Hanover Insurance (NYSE:THG) traded at a new 52-week high today of $66.88. T ...

Recent 52-Week Low Surpassed in Shares o...

Shares of Taseko Mines (AMEX:TGB) traded at a new 52-week low today of $1.35. This new ...

Transglobe Energy Looks to Continue to T...

Shares of Transglobe Energy (NASDAQ:TGA) traded today at $4.35, breaking its 52-week lo ...

Shares of TFS Financial Rise Above Previ...

Shares of TFS Financial (NASDAQ:TFSL) traded today at $15.09, breaking its 52-week high ...

Watch for Continued Gains in Shares of T...

Teva Pharmaceutical Industries (NASDAQ:TEVA) traded at a new 52-week high today of $55. ...

Shares of Integrys Energy Rise to a New ...

Integrys Energy (NYSE:TEG) traded at a new 52-week high today of $72.23. So far today ...